東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Intellectual Property and Biotechnol...

Allen, Clarissa.

FindBook

Google Book

Amazon

博客來

Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence./
作者:	Allen, Clarissa.
面頁冊數:	68 p.
附註:	Source: Masters Abstracts International, Volume: 50-02, page: .
Contained By:	Masters Abstracts International50-02.
標題:	Ethics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR75855
ISBN:	9780494758557

Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence.
Allen, Clarissa.

Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence. - 68 p.

Source: Masters Abstracts International, Volume: 50-02, page: .

Thesis (M.A.)--McGill University (Canada), 2011.

DNA patents have been being granted since the 1970s. Patents are meant to act as incentives, encouraging innovation and dissemination in biotechnology by granting inventors exclusive economic control of their inventions for a set period of time. Governments in North America and Europe have therefore been using patents as a public policy tool to encourage the invention of health-related biotechnologies since the 1980s and 1990s, respectively. However despite this laudable policy goal, there have also in recent decades been a number of controversies related to patenting in biotechnology. Commentators are concerned that patents may in fact be having a detrimental effect on innovation of and access to health-related products and processes. While empirical evidence that has been collected to date in relation to these concerns remains inconclusive, the debate may be clarified through the articulation of the rights and responsibilities that are at stake. The scope and content of a human right to healthcare are ultimately society-dependent, but its articulation can clarify whether instrumental property rights granted to inventors are interfering with this right in an unacceptable way. Intellectual property rights in health-related biotechnologies cannot be justified from a theoretical perspective, and so more definitive empirical data elucidating the role that patents play in regards to innovation and dissemination of health-related biotechnology is needed.

ISBN: 9780494758557Subjects--Topical Terms:

517264
Ethics.

Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence.
LDR:02302nam 2200277 4500 001 1405838
005 20111214135025.5
008 130515s2011 ||||||||||||||||| ||eng d
020 $a 9780494758557
035 $a (UMI)AAIMR75855
035 $a AAIMR75855
040 $a UMI $c UMI
100 1 $a Allen, Clarissa. $3 1685262
245 1 0 $a Intellectual Property and Biotechnology: Theoretical Arguments and Empirical Evidence.
300 $a 68 p.
500 $a Source: Masters Abstracts International, Volume: 50-02, page: .
502 $a Thesis (M.A.)--McGill University (Canada), 2011.
520 $a DNA patents have been being granted since the 1970s. Patents are meant to act as incentives, encouraging innovation and dissemination in biotechnology by granting inventors exclusive economic control of their inventions for a set period of time. Governments in North America and Europe have therefore been using patents as a public policy tool to encourage the invention of health-related biotechnologies since the 1980s and 1990s, respectively. However despite this laudable policy goal, there have also in recent decades been a number of controversies related to patenting in biotechnology. Commentators are concerned that patents may in fact be having a detrimental effect on innovation of and access to health-related products and processes. While empirical evidence that has been collected to date in relation to these concerns remains inconclusive, the debate may be clarified through the articulation of the rights and responsibilities that are at stake. The scope and content of a human right to healthcare are ultimately society-dependent, but its articulation can clarify whether instrumental property rights granted to inventors are interfering with this right in an unacceptable way. Intellectual property rights in health-related biotechnologies cannot be justified from a theoretical perspective, and so more definitive empirical data elucidating the role that patents play in regards to innovation and dissemination of health-related biotechnology is needed.
590 $a School code: 0781.
650 4 $a Ethics. $3 517264
650 4 $a Philosophy. $3 516511
650 4 $a Intellectual Property. $3 782112
650 4 $a Patent Law. $3 1679968
690 $a 0394
690 $a 0422
690 $a 0513
690 $a 0562
710 2 $a McGill University (Canada). $b Department of Philosophy. $3 1685263
773 0 $t Masters Abstracts International $g 50-02.
790 $a 0781
791 $a M.A.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=MR75855